Trials / Completed
CompletedNCT00727948
The Effect of Aspirin on Angiogenesis Proteins in Women on Tamoxifen Therapy
The Impact of the Anti-Platelet Agent Aspirin on Angiogenesis Proteins in Women With Breast Cancer
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- University of Vermont · Academic / Other
- Sex
- Female
- Age
- 18 Years – 95 Years
- Healthy volunteers
- Not accepted
Summary
Changes in major angiogenic proteins have been seen following initiation of tamoxifen and aromatase inhibitor therapy in women with breast cancer. One source of these proteins is the circulating platelet pool. The investigators hypothesize that in addition to their anti-platelet properties, agents such as aspirin can be used as targeted anti-angiogenesis therapy. The investigators will determine the influence of aspirin on the release of angiogenic proteins from platelets in 35 patients with breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aspirin | 325 mg tablets, once daily for 45 days |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2010-12-01
- Completion
- 2012-12-01
- First posted
- 2008-08-04
- Last updated
- 2020-09-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00727948. Inclusion in this directory is not an endorsement.